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Objective: Autoimmune thyroid disease (AITD) is an organ-specific disorder due to 
the interplay between environmental and genetic factors. Toll-like receptors (TLRs) are 
pattern recognition receptors expressed abundantly on monocytes. There is a paucity of 
data on TLR expression in AITD. The aim of this study was to examine TLR expression, 
activation, ligands, and downstream signaling adaptors in peripheral blood mononuclear 
cells (PBMCs) extracted from untreated AITD patients and healthy controls.
Method: We isolated PBMC of 30 healthy controls, 36 patients with untreated 
Hashimoto’s thyroiditis, and 30 patients with newly onset Graves’ disease. TLR mRNA, 
protein expression, TLR ligands, and TLR adaptor molecules were measured using 
real-time PCR, Western blot, flow cytometry, and enzyme-linked immunosorbent assay 
(ELISA). PBMC was simulated with TLR agonists. The effects of TLR agonists on the 
viability of human PBMC were evaluated using the MTT assay. The supernatants of 
cell cultures were measured for the pro-inflammatory cytokines, interleukin (IL)-6, tumor 
necrosis factor alpha (TNF-α), and IL-10 by ELISA.
results: TLR2, TLR3, TLR9, and TLR10 mRNA were significantly increased in AITD patients 
compared with controls. TLR2, TLR3, TLR9, high mobility group box 1 (HMGB1), and RAGE 
expression on monocytes was higher in patients than control at baseline and TLR agonists’ 
stimulation. The release of TNF-α and IL-6 was significantly increased in PBMCs from AITD 
patients with TLR agonists, while IL-10 was significantly decreased. Downstream targets 
of TLR, myeloid differentiation factor 88 (MyD88), and myeloid toll/IL-1 receptor-domain 
containing adaptor-inducing interferon-β were significantly elevated in AITD patients. Levels 
of TLR2 ligands, HMGB1, and heat shock protein 60 were significantly elevated in AITD 
patients compared with those in controls and positively correlated with TgAb and TPOAb, 
while sRAGE concentration was significantly decreased in AITD patients.
conclusion: This work is the first to show that TLR2, TLR3, and TLR9 expression and 
activation are elevated in the PBMCs of patients with AITD and TLRs may participate in 
the pathogenesis of AITD.
Keywords: autoimmune thyroid disease, innate immunity, toll-like receptor, signaling, pathogenesis
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inTrODUcTiOn
Autoimmune thyroid disease (AITD), which includes Hashimoto’s 
thyroiditis (HT) and Graves’ disease (GD) (1), is an organ-
specific autoimmune condition that affects approximately 2–3% 
of the population in China. HT is characterized by substantial 
infiltration of thyroid-specific T and B lymphocytes and thyroid 
gland damage, eventually leading to hypothyroidism (2). GD is an 
autoimmune disorder characterized by the presence of autoanti-
bodies that bind to and stimulate the thyroid stimulating hormone 
receptor, resulting in hyperthyroidism and goiter (3). Other than 
genetic and environmental factors, immune malfunction may 
also be involved in the development of AITD (4). Although the 
production of autoantibodies destroys self-tolerance and agita-
tion of the adaptive immune system, the fundamental mechanism 
remains unclear.
Recent studies have demonstrated that aberrant activation 
of the innate immune response may have a significant effect on 
the pathogenesis of AITD. Due to an improved understanding 
of pattern recognition receptors, insight into innate immunity 
has expanded dramatically. Toll-like receptors (TLRs) are 
conserved pattern recognition receptors expressed on multiple 
types of cells, including monocytes, dendritic cells, B cells, and 
macrophages, and play a vital role in modulation of the innate 
immune system (5). TLRs recognize conserved molecules 
termed pathogen-associated molecular patterns (PAMPs), such 
as bacteria, viruses, and fungi, which act as ligands of specific 
TLR-induced signal transduction pathways (6), resulting in the 
activation of innate immune response and the release of inflam-
matory mediators, including interleukin (IL)-6, IL-12, IL-18, 
and tumor necrosis factor alpha (TNF-α). TLRs can also bind 
to certain endogenous molecules called damage-associated 
molecular patterns (DAMPs) and activate the innate immune 
response. Accordingly, TLRs have the ability to stimulate the 
production of monocytes and other antigen-presenting cells 
via activation of TLRs signaling pathways. To date, nothing is 
known regarding the ligands or cellular localization of TLR10, 
which is expressed only in humans (7). It is possible that TLR10 
serves as a co-receptor for TLR2 (8). Ligands of TLR2 and TLR4 
include heat shock protein 60 (HSP60), HSP70, hyaluronan, 
high mobility group box 1 (HMGB1), and advanced glycation 
end products (9). HSP60, the first endogenous ligand to be 
discovered, is an intramitochondrial chaperone that facilitates 
protein folding and stability (10). HSP60 also induce autoim-
mune responses by acting as a decoy to stimulate  autoantibodies 
(11). HMGB1 has been described as a late inflammatory 
cytokine in several autoimmune diseases, such as rheumatoid 
arthritis (RA) (12) and systemic lupus erythematosus (SLE) 
(13). HMGB1 also plays a vital role in the initiation and pro-
gression of allograft rejection by acting as a “danger signal” 
(alarmin) (14). HMGB1 can interact with TLR2, TLR4, TLR9, 
and the receptor for advanced glycation end products (RAGE), 
thus inducing activation of TLR signaling. Once stimulated by 
ligands, TLRs recruit downstream adaptor molecules, includ-
ing toll/IL-1 receptor-domain containing adaptor-inducing 
interferon-β (TRIF) and myeloid differentiation factor 88 
(MyD88), resulting in signaling pathway activation and in the 
production of pro-inflammatory cytokines, such as IL-6 and 
TNF-α (15).
Toll-like receptors play an important role in the development 
of inflammatory disease. Previous studies have shown that TLRs 
are involved in the development of several autoimmune diseases, 
such as SLE, type 1 diabetes, and RA (16). TLR7 has been demon-
strated to be involved in the production of autoantibodies and thus 
plays a vital role in the pathogenesis of SLE (17). TLR3, TLR7, and 
TLR9 are elevated in RA synovial fibroblasts (18), and a significant 
increase in TLR2 and TLR4 and their ligands has been described 
in T1DM patients (19, 20). In contrast, there is a paucity of stud-
ies regarding the role of TLR in AITD. Nonetheless, it has been 
demonstrated that TLR3 is highly expressed in thyrocytes from 
patients with HT (21), and increased expression of TLR3 was 
also observed in thyroid follicular epithelial cells from patients 
with GD (22). TLR3 signaling is activated by viral and bacterial 
molecules, dsRNA and poly (I:C), a synthetic viral analog, which 
results in the production of pro-inflammatory cytokines and 
interferons (IFNs) (22). It has also been demonstrated that TLR4 
is expressed in FRTL-5 cells, leading to activation of NF-κB via 
recognition of LPS (23).
Although such findings based on animal and human thyroid 
gland investigations suggest that TLRs may play an important 
role in AITDs, it remains unclear whether activation of TLR 
pathways results in inflammation in AITD patients. The aim 
of the current study was to analyze TLR expression, activation, 
ligands, and downstream signaling adaptors in peripheral blood 
mononuclear cells (PBMCs) extracted from untreated AITD 
patients and healthy controls.
MaTerials anD MeThODs
study groups
In this particular study, 4 mL fresh blood was obtained from 36 
patients with HT, 30 patients with GD, and 30 age- and sex-matched 
controls. PBMCs were prepared from all samples. Serum samples 
were obtained from these patients. All patients were recruited 
from the First Affiliated Hospital of China Medical University. All 
participants provided a detailed history and underwent a com-
plete physical examination as a condition of participation. None 
of the patients were taking evothyroxine or any other antithyroid 
drug. Subjects with any chronic disease, infectious disease, cancer, 
diabetes, or a family history of diabetes were excluded from this 
study. Levels of serum thyrotropin (TSH), free T3 (FT3), free T4 
(FT4), TPOAb, TgAb, and thyrotrophin receptor antibody were 
analyzed using an electrochemiluminescent immunoassay with 
Cobas Elesys 601 (Roche Diagnostics Ltd., Switzerland). These 
samples were stored until use.
This experiment was approved by the Ethics Committee of the 
First Affiliated Hospital of China Medical University, and written 
informed consent was provided by each subject.
Peripheral Blood Mononuclear cell 
isolation and Tlr agonist stimulation
Peripheral blood mononuclear cells were obtained from freshly 
collected blood in heparinized tubes, isolated by Ficoll-isopaque 
TaBle 1 | sequence of primers used to amplify.
genes Forward primer reverse primer
TLR1 GGATGCAGAAGGAGATCACTG TTTCAAAAACCGTGTCTGTTAAGAGA
TLR2 GGAGGCTGCATATTCCAAGG GCCAGGCATCCTCACAGG
TLR3 CAGTGTCTGGTACACGCATGGA TTTCAAAAACCGTGTCTGTTAAGAGT
TLR4 AGTTTCCTGCAATGGATCAAGG CTGCTTATCTGAAGGTGTTGCA
TLR5 GGCTTAATCACACCAATGTCACTATAG TTAAGACTTCCTCTTCATCACAACCTT
TLR6 CATCCTATTGTGAGTTTCAGGCAT GCTTCATAGCACTCAATCCCAA
TLR7 TGGAAATTGCCCTCGTTGTT GTCAGCGCATCAAAAGCATT
TLR8 AGCGGATCTGTAAGAGCTCCATC CCGTGAATCATTTTCAGTCAAGAC
TLR9 AGCGGATCTGTAAGAGCTCCATC CCGTGAATCATTTTCAGTCAAGA
TLR10 AAGAAAGGTTCCCGCAGACTT TGTTATGGCATAGAATCAAAACTCTCA
GAPDH CAA AGACCTGTACGCCAACA GAAGCATTTGCGGTGGAC
3
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density gradient centrifugation (Gibco BRL, Life Technologies 
Ltd., Paisley, UK), as described previously (24), and washed 
free of platelets and Ficoll. PBMCs were harvested and washed 
twice in RPMI 1640 (Gibco BRL, Life Technologies Ltd., Paisley, 
UK). The cells were diluted with complete medium consisting of 
RPMI 1640 supplemented with 10% fetal calf serum, 2 mmol/L 
glutamine, 100 U/mL penicillin G, and 100 U/mL streptomycin 
to 1 ×  106/mL. Cells were then dispensed in a 200-μL tube in 
96-well plates. Pam3CSK4, Poly I:C, and CpG ODN were used 
as TLR2, TLR3, and TLR9 agonists, respectively. Each volume 
containing 1 × 106 isolated PBMCs were incubated with medium, 
1 μg/mL Pam3CSK4, 10 μg/mL poly I:C, and 1 μg/mL CpG ODN 
for 2, 6, 8, 12, 24 and 48 h at 37°C in 5% CO2. The supernatants 
were harvested and collected at −20°C until further use.
Quantitative mrna expression  
of Tlrs in PBMcs
RNA was extracted from PBMC, using TRIzol (Invitrogen Corp., 
CA, USA). The first strand of cDNA was synthesized using 
total RNA. RT-PCR was performed using TagMan gene expres-
sion assays, with glyceraldehydes-3-phosphatedehydrogenase 
(GAPDH) as a control (R&D Systems, Minneapolis, MN, 
USA). The sequences of primers for TLR1-10 and GAPDH were 
designed using the ABI PRISM system (Applied Biosystems). 
Sequences of the human primers for polymerase chain reaction 
were as summarized in Table 1. The primers were examined with 
BLAST software against the National Center for Biotechnology 
Information database. All PCRs were performed in a total volume 
of 20 μL, and single transcript of genes expression was determined 
using SYBR green master mix. Relative expression of TLR1-10 
was calculated using the comparative cycle threshold method. 
TLR1-10 mRNA was expressed as a ratio to GAPDH.
In Vitro studies on PBMc from aiTD 
Patients and controls cell Viability assay
The effect of TLR agonists on the viability of human PBMC 
was analyzed by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetra-zolium bromide] assay. PBMC were maintained in 
RPMI-1640 medium, supplemented with 10% fetal bovine serum, 
and 1% penicillin/streptomycin, under 37°C, 95% humidified air 
and 5% CO2. MTT was added to each well to a final concentration 
of 10  mg/L and the cells were continuously incubated for 5  h. 
After centrifugation for 5 min at 3,000 × g, the supernatant was 
removed and the wells were washed three times with PBS before 
addition of 100 mL isopropyl alcohol to dissolve MTT crystals 
and optical density (OD) was determined at 550 nm using micro 
enzyme-linked immunosorbent assay (ELISA) plate reader (Bio-
Rad, Hercules, CA, USA). All measurements were performed in 
triplicate. Stimulation index was calculated as mean ratio of OD 
of the stimulated cells divided by OD of untreated cells.
Tlr2, Tlr3, Tlr9, hMgB1, and rage 
expression in the resting state and upon 
specific agonist activation
Peripheral blood mononuclear cells were analyzed under 
resting and after 24  h stimulation with TLR2, 3, or 9 agonists. 
PBMCs were resuspended in PBS and stained for surface mAbs 
CD14-FITC (eBioscience, San Diego, CA, USA) and TLR2-APC 
(eBioscience, San Diego, CA, USA). After 15 min of incubation 
at room temperature in the dark, cells were washed and fixed 
in 1% paraformaldeyde in PBS. Cells were then permeabilized 
with saponin 0.5% (Sigma-Aldrich, St. Louis, MO, USA) and 
mAbs for TLR3-APC and TLR9-APC, with unconjugated mouse 
anti-human HMGB1 monoclonal antibody (Abcam, Cambridge, 
UK), unconjugated mouse anti-human RAGE polyclonal anti-
body (Millipore, MA, USA) or its corresponding mouse IgG 
isotype control (BD Biosciences Corp., San Jose, CA, USA) with 
subsequence incubation with APC-conjugated goat anti-mouse 
secondary antibody (Santa Cruz Biotechnology, CA, USA). Cells 
were incubated for 45 min at 4°C in the dark, washed, and fixed 
in 1% paraformaldeyde in PBS. Samples were then analyzed 
using BD FACS Array (Becton-Dickinson, Fullerton, CA, USA) 
equipped with software Cellquest.
Results are expressed as percentages of CD14+ TLR2+, CD14+ 
TLR3+, CD14+ TLR9+ cells, CD14+ HMGB1+, and CD14+ RAGE+. 
The intra- and inter-assay CVs for TLR2, TLR3, TLR9, HMGB1, 
and RAGE expression were found to be <5, <5, <15, <5, <10, 
and <15%, respectively.
cytokine Production
Interleukin-6, IL-10, and TNF-α were examined in the super-
natants of the cultured PBMCs in AITD patients and healthy 
subjects after TLR agonist stimulation using commercially 
available ELISA kits (R&D, Minneapolis, MN, USA) according 
to the manufacturer’s instructions. Absorbance was measured 
at a wavelength of 450 nm using a microplate reader to analyze 
TaBle 2 | The clinical characteristics of patients with hashimoto’s thyroiditis, graves’ disease, and healthy controls.
Variable hc hT gD normal range
No. 30 36 30 –
Age (years) 37 ± 8 34 ± 9 30 ± 9 –
Gender (M/F) 4/26 4/32 5/25 –
Thyrotropin (mIU/L) 1.3 ± 0.2 14.2 ± 3.16 0.007 ± 0.01 0.35–4.94
FT4 (ng/dL) 1.4 ± 0.1 0.9 ± 0.2 46.02 ± 14.7 9.01–19.05
FT3 (pg/mL) 2.6 ± 0.5 3.7 ± 0.2 34.3 ± 6.9 2.63–5.70
Thyrotrophin receptor antibody (IU/L) – – 37.6 ± 9.5 0–1
TPOAb (IU/mL) 5.03 ± 0.7 343.27 ± 126.2 167.5 ± 23.2 0.11–5.23
TgAb (IU/mL) 2.54 ± 0.5 433.45 ± 102.7 192.28 ± 17.32 0.81–3.83
Data are expressed as mean ± SD. The “–” represents that the experiment was not performed, or the data are not applicable.
M, male; F, female; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; HC, healthy controls.
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the intensity of color development in each well. The levels of 
cytokines were presented as picogram per milliliter.
Western Blot analysis
Western blot was used to detect protein in PBMC of AITD 
patients and controls. Frozen cells were homogenized in PBS 
(pH 7.4) supplemented with 0.05% Triton X-100 and protease 
inhibitor cocktail (Sigma). The protein concentration was deter-
mined using the Bradford method with BSA as the standard. 
SDS-PAGE was performed using 30% acrylamide (Sigma). After 
electrophoresis, gels were equilibrated for 20  min in transfer 
buffer (25  mM Tris, 190  mM glycine, and 20% methanol). 
Proteins were transferred onto polyvinylidene difluoride 
membranes (0.5  h, 30  V), which were then incubated with a 
blocking solution [5% dried skim milk in 100  mM Tris (pH 
7.5) with 140 mM NaCl and 0.01% Tween 20 for a minimum 
of 1.5 h]. The blots were then incubated overnight at 4°C, either 
with a polyclonal rabbit anti-TRIF antibody (1:800, Abcam, 
UK), a polyclonal rabbit anti-MyD88 antibody (1:800, Abcam, 
UK), or a polyclonal rabbit anti-β-actin (1:1,000) on the same 
membrane. The blots were washed three times with the blocking 
solution and incubated with diluted horseradish-peroxidase-
conjugated secondary antibodies (1:1,000) (Bio-Rad) for 
1.0  h at room temperature. Blots were washed extensively 
and developed using an enhanced chemiluminescence kit 
(Amersham Pharmacia Biotech, Piscataway, NJ, USA). Western 
immunoblot bands were quantified by means of a Bio-Rad 
calibrated densitometer (GS-800) using the vendor’s software 
(Bio-Rad Laboratories) and β-actin served as an internal control 
for all analyses.
serum levels of hMgB1, hsP60, and 
srage
Serum levels of HMGB1, HSP60, and sRAGE were measured 
using commercially available ELISA kits (R&D, Minneapolis, 
MN, USA). The procedures were performed in accordance with 
the manufacturer’s instructions. Absorbance was measured at a 
wavelength of 450 nm using a microplate reader to analyze the 
intensity of color development in each well. The levels of HMGB1 
and HSP60 were presented as nanograms per milliliter, whereas 
sRAGE was presented as picograms per milliliter.
statistical analysis
All statistical analyses were performed using SPSS Software 
20.0 (SPSS, Inc., Chicago, IL, USA). Results are displayed as 
mean ±  SD. The normally distributed data were analyzed by 
independent-samples t-test. Meanwhile, the analysis of abnor-
mally distributed data was performed with Kruskal–Wallis test 
followed by the Mann–Whitney U test. One-way ANOVA was 
used to compare three experimental groups. The correlation 
between serum levels and clinical variables was analyzed using 
the Spearman’s method. P-values <0.05 were considered statisti-
cally significant.
resUlTs
elevated expression of Tlr2, Tlr3, Tlr9, 
and Tlr10 in PBMcs of aiTD Patients
Blood samples were obtained in 66 AITD patients and 30 healthy 
controls. The clinical features of enrolled subjects are shown in 
Table 2. In this study, the levels of expression of TLR1–TLR10 in 
PBMC samples from AITD patients (30 with untreated GD and 
36 with HT) and 30 healthy subjects were assessed by RT-PCR 
were examined. As shown in Figure 1, the mRNA expression of 
TLR1, 4, 5, 6, 7, and 8 was equivalent between in AITD patients 
and healthy controls. The expression of TLR2, TLR3, TLR9, and 
TLR10 were significantly increased in both with HT (P < 0.05, 
P < 0.05, P < 0.01, and P < 0.05, respectively) and those with GD 
subjects (P < 0.05, P < 0.01, P < 0.01, and P < 0.05, respectively) 
than in controls, but no difference was found between HT and 
GD patients for all of these TLR.
Proliferative response to Tlr agonists 
from PBMcs with aiTD and hc
As shown in Figure 2, we found that PBMC from AITD patients 
significantly proliferated compared to controls (P < 0.05 for HT 
and GD, respectively). Increased OD was also found in AITD 
patients’ in vitro stimulation with TLR2 agonist (P < 0.01 for HT 
and GD, respectively). Similarly, there are increased OD in AITD 
patients when cultured with TLR3 and TLR9 agonists (P < 0.01 
and P < 0.01 for Poly I:C and P < 0.05 and P < 0.01 for CpG 
ODN, respectively).
FigUre 1 | Toll-like receptor (Tlr) mrna expression in peripheral blood mononuclear cells (PBMcs).  
(Continued )
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FigUre 2 | cell viability in peripheral blood mononuclear cells after 
toll-like receptor (Tlr) agonists stimulation. Bar graphs comparing of 
cell viability optical density between unstimulated and stimulated cells treated 
with either unstimulate or stimulate of TLR agonists in both AITD patients and 
controls by MTT assay. Each bar represents the mean ± SD of three groups. 
One-way ANOVA was used to compare the differences of expression 
between AITD patients and healthy controls. AITD, autoimmune thyroid 
disease; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; HC, healthy 
controls. Pam3CSK4, Poly I:C, and CpG ODN were used as TLR2, TLR3, 
and TLR9 agonists, respectively. Level of significant is *P < 0.05 and 
**P < 0.01.
Bar graphs comparing TLR1–TLR10 mRNA expression levels in PBMCs from patient with Hashimoto’s thyroiditis, Graves’s disease, and healthy controls. TLRs 
expression was measured by real-time PCR using GAPDH as endogenous control. Results are shown as fold change regarding TLRs gene expression in AITD 
patients relative to healthy subjects. Each bar represents the 1 ± SEM of three groups. One-way ANOVA was used to compare the differences of expression 
between AITD patients and healthy controls. AITD, autoimmune thyroid disease; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; HC, healthy controls. Level of 
significant is *P < 0.05 and **P < 0.01.
FigUre 1 | continued
6
Peng et al. Toll-Like Receptors in Autoimmune Thyroid Diseases
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 578
Time-Dependent Modulation of Tlr2, 
Tlr3, Tlr9, hMgB1, and rage 
expression in PBMcs by specific agonist 
activation
To further characterize regulation of TLR expression by specific 
agonists, a time–response study was conducted. In PBMCs from 
healthy controls stimulated with specific TLR agonists for 2, 6, 8, 
12, 24, and 48 h, the maximal response for TLR2, TLR3, TLR9, 
HMGB1, and RAGE protein expression was all observed at 24 h 
(all P < 0.05, Figure 3), and the expression significant reduced at 
48 h, suggesting that 24 h is the optimal time for the PBMCs by 
TLR agonists stimulation.
responses of cD14+ cells from aiTD and 
hc to Tlr2, Tlr3, and Tlr9 stimulation 
with Pam3csK4, Poly i:c, and cpg ODn
Intracellular and surface expression upon TLR stimulation in 
CD14+ cells were analyzed in PBMCs from AITD and control 
subjects. The expression of TLR2 was analyzed in HT, GD, and 
HC groups of CD14+ monocytes cells after cultured for 24 h in the 
presence or absence of Pam3CSK4. As shown in Figure 4A, the 
percentage of CD14+ TLR2 monocytes was significantly higher 
in AITD patients than in controls in resting and Pam3CSK4 
activation (P <  0.01 and P <  0.01, respectively). Similarly, in 
both resting and agonist-stimulated cultured cells, TLR3 and 
TLR9 expression on peripheral CD14+ monocytes expression 
in AITD patients was significantly higher than in the control 
group (P < 0.05 and P < 0.05; P < 0.01 and P < 0.01 respectively, 
Figures 4B,C). TLR2, TLR3, and TLR9 expression did not differ 
between GD and HT patients (Table 3).
responses of cD14+ cells from aiTD and 
hc to hMgB1 and rage stimulation with 
cpg ODn
The expression of HMGB1 and RAGE were analyzed in HT, GD, 
and HC groups of CD14+ monocytes cells when cultured with 
TLR9 agonist, CpG ODN. As shown in Figure 5A, the percentage 
of CD14+ HMGB1 monocytes was significantly higher in AITD 
patients than in controls in resting (11.3 ± 2.0 for HT, 10.6 ± 1.8 
for GD Vs 6.5 ± 1.2 for HC) and CpG ODN activation (14.7 ± 2.2 
for HT, 13.8 ±  2.6 for GD Vs 10.5 ±  2.1 for HC; all P <  0.01, 
respectively). Similarly, the percentage of CD14+ RAGE+ cells 
in AITD patients was significantly higher than those in control 
group in both resting (4.7 ±  0.7 for HT, 4.3 ±  0.5 for GD Vs 
2.3 ± 0.4 for HC) and agonist-stimulated cultured cells (4.9 ± 0.8 
for HT, 5.0 ± 0.7 for GD Vs 3.0 ± 0.5 for HC; P < 0.01 for HT and 
P < 0.01 for GD, respectively, Figure 5B).
The expression of TnF-α, il-6, and il-10 
in PBMcs stimulated with Tlr2, Tlr3, 
and Tlr9 agonists Pam3csK4, Poly i:c, 
and cpg ODn
To determine whether TLR activation can induce cytokine 
upregulation in AITD patients, we examine the cytokine in 
TLR agonist activation PBMCs from AITD patients and healthy 
controls. TNF-α, IL-6, and IL-10 expression were evaluated 
in the culture supernatant of PBMCs after stimulation with 
Pam3CSK4, Poly I:C, and CpG ODN for 24  h. As shown in 
Figure 6A, the TNF-α expression in AITD patients, including 
GD and HT patients, were found to be significantly higher than 
those for control subjects when stimulated with either Poly I:C 
(TLR3) or CpG ODN (TLR9) (P < 0.01 and P < 0.01 for Poly 
I:C and CpG ODN, respectively). However, the expression of 
TNF-α in response to Pam3CSK4, a ligand of TLR2, appeared 
to be the same in all three groups. As shown in Figure 6B, the 
IL-6 secretion levels from PBMC samples stimulated with either 
Pam3CSK4, Poly I:C, or CpG ODN in the AITD groups were also 
found to be significantly higher than those in the control group 
(P < 0.05, P < 0.05, and P < 0.01 for Pam3CSK4, Poly I:C, and 
CpG ODN, respectively), while IL-10 expression, were signifi-
cantly decreased in AITD groups under stimulation (P < 0.01, 
FigUre 3 | Time-dependent modulation of Tlr2, Tlr3, Tlr9, high mobility group box 1 (hMgB1), and receptor for advanced glycation end products 
(rage) expression in peripheral blood mononuclear cells (PBMcs) by specific agonist activation. PBMCs from healthy controls were treated with a TLR2, 
TLR3, or TLR9 agonist for 0, 2, 6, 8, 12, 24, and 48 h stained with anti-CD14 and anti-TLR2, TLR3, TLR9, HMGB1, and RAGE mAbs for flow cytometry. 
Percentages of CD14+TLR2+ (a), CD14+TLR3+ (B), CD14+TLR9+ (c), CD14+HMGB1+ (D), CD14+RAGE+cells (e) from HC was measured by flow cytometry. Results 
are shown as mean ± SD of control group. Level of significant is *P < 0.05. Statistical analyses were conducted using one-way ANOVA. Pam3CSK4, Poly I:C, and 
CpG ODN were used as TLR2, TLR3, and TLR9 agonists, respectively.
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P < 0.01, and P < 0.01 for Pam3CSK4, Poly I:C, and CpG ODN, 
respectively, Figure 6C).
Downstream Proteins under  
Western Blot analysis
The downstream proteins TRIF and MyD88 were analyzed by 
Western blot analysis. As shown in the Figures 7A,B, the expres-
sion of TRIF was significantly higher in PBMC samples from HT 
and GD patients than in those from healthy subjects (P < 0.01 
and P < 0.01, respectively). There was no significant difference 
between the HT and GD subjects.
MyD88 expression in HT and GD groups was also signifi-
cantly higher than in HC group (P < 0.01; P < 0.01, respectively. 
Figures 7A,C). No significant difference was found between HT 
and GD groups.
elevated hMgB1, hsP60, and srage  
in the serum of aiTD Patients
The serum levels of HMGB1 were significantly higher in 
patients with HT (37.81  ±  12.26  ng/mL) and in patients 
with GD (40.03  ±  13.40  ng/mL) than in control subjects 
(17.54  ±  4.94  ng/mL, P  <  0.01, and P  <  0.01, respectively, 
Figure 8A). Similarly, the HSP60 levels were also higher in HT 
(135.33 ±  18.63  ng/mL) and GD groups (140.55 ±  19.81  ng/
mL) than in control subjects (68.99 ±  18.34 ng/mL, P <  0.01, 
and P <  0.01, respectively, Figure 8B). In addition, the serum 
levels of HMGB1 and HSP60 did not differ between GD and 
HT patients. In contrast, there was a significantly decreased 
expression of sRAGE in HT (1,276.67  ±  98.47  pg/mL) and 
GD patients (1,278.08 ± 92.54 pg/mL) than in healthy subjects 
(1,433.80 ± 92.48 pg/mL, P < 0.01, and P < 0.01, respectively, 
Figure  8C).
correlation of hMgB1, hsP60, and  
srage with clinical Variables
No significant correlation was found between either HMGB1, 
HSP60, or sRAGE levels and serum levels of TSH, FT3, or 
FT4 in HT patients. However, HMGB1 showed a significant 
association with TPOAb and TgAb in HT patients (r = 0.5716, 
P < 0.001, Figure 9A; r = 0.5914 P < 0.001, Figure 9B). There 
was also a significant correlation between HSP60 and TPOAb 
(r  =  0.4074, P  <  0.001, Figure  9C) and TgAb (r  =  0.4815 
P < 0.001, Figure 9D) in HT patients. However, no significant 
correlations were found between sRAGE expression and clinical 
variables.
DiscUssiOn
Autoimmune thyroid diseases are characterized by production 
of pathogenic thyroid autoantibodies and lymphocyte infiltration 
FigUre 4 | Tlr2, Tlr3, and Tlr9 surface protein expression in monocytes after toll-like receptor agonists stimulation.  
(Continued )
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TaBle 3 | Percentage of Tlr2, Tlr3, and Tlr9 expressing cD14+ cells in basal condition and after stimulation of aiTD and hc PBMcs with Pam3csK4 
(Tlr2), Poly i:c (Tlr3), and cpg ODn (Tlr9) for 24 h.
Basal Pam3csK4 Poly i:c cpg ODn
Tlr2 Tlr3 Tlr9 Tlr2 Tlr3 Tlr9
HC 7.6 ± 2.0 2.6 ± 0.3 5.1 ± 1.0 9.3 ± 2.7 3.2 ± 0.7 6.6 ± 1.2
HT 11.8 ± 2.1 4.1 ± 0.7 7.4 ± 1.2 13.8 ± 1.8 5.0 ± 0.6 9.8 ± 2.0
GD 11.0 ± 2.7 4.4 ± 0.8 7.9 ± 0.9 13.5 ± 2.9 5.3 ± 0.8 10.4 ± 1.9
Results are shown as mean ± SD of three groups.
AITD, autoimmune thyroid disease; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; HC, healthy controls.
Pam3CSK4, Poly I:C, and CpG ODN were used as TLR2, TLR3, and TLR9 agonists, respectively.
Peripheral blood mononuclear cells from AITD patients and healthy controls were treated with a TLR2, TLR3, or TLR9 agonist or PBS as basal for 24 h and stained 
with anti-CD14 and anti-TLR2, TLR3, and TLR9 mAbs for flow cytometry. We first selected singlets using forward scatter area Vs forward scatter height 
parameters. From the singlet population, we removed dead cells from total events by gating on LIVE/DEAD events. Then, we selected total monocytes from the 
living using the pan-monocyte marker CD14, then TLR2 positive, TLR3 positive, and TLR9 positive, respectively. (a) Flow cytometry dot plots from AITD and HC 
depicting TLR2 expression by CD14 enriched monocyte cells (left panels). The number in the right quadrants represents the percentage of CD14+TLR2+ between 
AITD and healthy controls. (B) Flow cytometry dot plots from AITD and HC depicting TLR3 expression by CD14 enriched monocyte cells (left panels). Percentages 
of CD14+TLR3+ cells were compared between HC and AITD patients (right panels). (c) Flow cytometry dot plots from AITD and HC depicting TLR9 expression by 
CD14 enriched monocyte cells (left panels). Percentages of CD14+TLR9+ cells were compared between HC and AITD patients (right panels). Each bar represents 
the mean ± SD of three groups. Level of significant is *P < 0.05 and **P < 0.01. AITD, autoimmune thyroid disease; HT, Hashimoto’s thyroiditis; GD, Graves’ 
disease; HC, healthy controls. Statistical analyses were conducted using one-way ANOVA. Pam3CSK4, Poly I:C, and CpG ODN were used as TLR2, TLR3, and 
TLR9 agonists, respectively.
FigUre 4 | continued
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(1). TLRs play a vital role in the increased inflammation observed 
in AITD, which may be mediated in part through activation of 
innate immune pathways by TLRs. However, no study to date has 
examined TLR expression in PBMCs from AITD patients or their 
contribution to the production of pro-inflammatory cytokines.
In the current study, mRNA expression of TLR2, -3, -9, 
and  -10 was significantly increased in patients with HT and 
GD compared with controls. Despite the lack of data regarding 
TLR in AITD, TLR3 has been found to be highly expressed by 
thyrocytes and thyroid follicular epithelial cells of HT and GD 
patients (21). TLR3 is also expressed in both thyroid follicles and 
inflammatory cells of iodine-induced NOD.H-2h4 mice (25), a 
classic model of spontaneous autoimmune thyroiditis (26). In 
addition, poly (I:C) administration aggravates inflammation of 
excessive iodine-induced thyroiditis in NOD mice, and evidence 
of the severity of thyroid follicle destruction and amount of 
lymphocyte infiltration has been reported (25). DNA microarray 
analysis has shown that stimulation of cultured human thyroid 
follicles with dsRNA [poly (I:C)] can cause activation of inflam-
matory responses and upregulation of a variety of related genes, 
including pro-inflammatory cytokines (IL-6) and chemokines 
(27). The results of the present study are consistent with previous 
studies suggesting that TLR3 may be involved in the development 
of AITD. In our study, mRNA expression of TLR2 was found to 
be elevated in AITD patients. It has been reported that FRTL-5 
cells express TLRs, including TLR2, TLR3, TLR4, and TLR9, 
and stimulate the expression of pro-inflammatory cytokine (27). 
Thyrocytes produce pro-inflammatory cytokines and type I IFNs 
in response to PAMPs and DAMPs, thereby activating the innate 
immune response (28). Here, we present evidence that TLR9 was 
more highly expressed in PBMCs from HT and GD patients com-
pared to controls. Although TLR9 has been demonstrated to be 
associated with SLE (29) and type 1 diabetes (30), there are limited 
data regarding the levels of TLR9 in AITD patients. A previous 
study demonstrated that TLR9 single-nucleotide polymorphisms 
(SNPs) play an important role in males with thyroid-associated 
ophthalmopathy (31). TLR9 recognizes the unmethylated CpG 
motif of microbial DNA and endogenous DNA, which acts as 
a PAMP and binds to TLR9 to stimulate signal transduction via 
the MyD88 pathway against viral pathogens. A recent study has 
shown a significant association between TLR10 SNPs and the 
mechanism of AITD in patients (32). TLR10 is expressed by 
immune-related cells and is more likely to interact with TLR1 and 
TLR6 than other TLRs. Although the ligands and the signaling 
of TLR10 remain unknown (7), it has been reported that TLR10 
functions as a co-receptor of TLR2 (33). The underlying mecha-
nism of TLR10 in AITD remains unknown. Further studies are 
needed to confirm the role of TLR10 in thyrocytes.
A remarkable increase in viability was found for PBMCs from 
AITD patients in the resting state and after TLR stimulation. This 
finding indicates that activation of TLR signaling triggers abnor-
mal activation of lymphocytes and stimulates and amplifies the 
immune response in AITD patients, which may lead to persisting 
autoimmunity.
TLR2, TLR3, and TLR9 surface expression is increased on 
monocytes from AITD subjects compared with controls. In 
addition, following specific agonist stimulation, the percent-
age of TLR2-expressing CD14+ cells increased in the PBMCs 
of both HT and GD patients, suggesting further activation 
of signaling pathways. Similarly, increased TLR3 and TLR9 
expression in AITD patients was also found under TLR3 and 
TLR9 stimulation. HMGB1 and RAGE expression was found 
to be upregulated in PBMCs from AITD patients in the rest-
ing state and under TLR9 stimulation. HMGB1, a nuclear 
FigUre 5 | high mobility group box 1 (hMgB1) and receptor for advanced glycation end products (rage) surface protein expression in monocytes 
after Tlr9 agonist stimulation. Peripheral blood mononuclear cells from AITD patients and healthy controls were treated with a TLR9 agonist or PBS as basal for 
24 h and stained with anti-CD14 and anti-HMGB1, and RAGE mAbs for flow cytometry. We first selected singlets using forward scatter area Vs forward scatter 
height parameters. From the singlet population, we removed dead cells from total events by gating on LIVE/DEAD events. Then, we selected total monocytes from 
the living using the pan-monocyte marker CD14, then HMGB1 positive and RAGE positive cells selected, respectively. (a) Flow cytometry dot plots from AITD and 
HC depicting HMGB1 or match isotype control expression by CD14 enriched monocyte cells (left panels). The number in the right quadrants represents the 
percentage of CD14+HMGB1+ between AITD and healthy controls. (B) Flow cytometry dot plots from AITD and HC depicting RAGE expression by CD14 enriched 
monocyte cells (left panels). Percentages of CD14+RAGE+ cells were compared between HC and AITD patients (right panels). Control cells were stained with the 
secondary antibodies without using the anti-RAGE primary antibody. Each bar represents the mean ± SD of three groups. Level of significant is *P < 0.05 and 
**P < 0.01. AITD, autoimmune thyroid disease; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; HC, healthy controls. Statistical analyses were conducted using 
one-way ANOVA. CpG ODN was used as a TLR9 agonist.
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protein released from damaged or necrotic cells, is involved 
in many chronic inflammatory diseases. The HMGB1–DNA 
complex binds to RAGE and then activates the TLR9-mediated 
inflammatory response (34), and a previous study showed that 
extracellular HMGB1 could bind to CpG ODN and stimulate 
its transfer to TLR9 in inflammatory disease (35). Our finding 
suggested that HMGB1 and RAGE play an important role in 
the development of chronic inflammation in AITD through 
the activation of TLR9 pathway.
Toll-like receptor activation has been demonstrated to have the 
ability to regulate the production of pro-inflammatory cytokines 
(36, 37). Our results showed increased IL-6 and decreased IL-10 
production in PBMCs from AITD patients in response to specific 
ligands for either TLR2, TLR3, or TLR9 and increased TNF-α 
expression in response to TLR3 and TLR9 ligands compared 
to healthy controls. Conversely, TNF-α secretion after TLR2 
agonist stimulation in PBMCs from AITD patients and controls 
was equivalent, suggesting that TNF-α production may not be 
FigUre 7 | Toll-like receptor (Tlr) signaling proteins in peripheral blood mononuclear cell from patients with hashimoto’s thyroiditis, graves’s 
disease, and healthy controls. (a) Representative Western blotting results of TLR downstream signaling proteins MyD88 and toll/IL-1 receptor-domain containing 
adaptor-inducing interferon-β (TRIF) was performed using specific antibodies to the respective proteins as described in methods. β-actin was used as loading and 
internal control for MyD88 and TRIF. (B) A ratio of TRIF/β-actin was determined to represent a mean net density. (c) A ratio of MyD88/β-actin was determined to 
represent a mean net density. Level of significant is *P < 0.05 and **P < 0.01. Values were shown as mean ± SD. HT, Hashimoto’s thyroiditis; GD, Graves’ disease; 
HC, healthy controls. One-way ANOVA was used to compare the differences of TRIF and MyD88 proteins of these three groups.
FigUre 6 | release of tumor necrosis factor alpha (TnF-α), interleukin (il)-6, and il-10 in the cultured supernatants from aiTD patients and healthy 
controls. (a) Peripheral blood mononuclear cells (PBMCs) isolated from subjects were stimulated with Pam3CSK4, poly I:C, and CpG ODN for 24 h, TNF-α were 
measured by enzyme-linked immunosorbent assay (ELISA). (B) PBMCs were treated as in (a) and the release of IL-6 was measured by ELISA. (c) PBMCs were 
treated as in (a) and the release of IL-10 was measured by ELISA. Level of significant is *P < 0.05 and **P < 0.01. Values were shown as mean ± SD and 
expressed as picograms per milliliter. AITD, autoimmune thyroid disease; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; HC, healthy controls. Statistical analyses 
were conducted using one-way ANOVA. Pam3CSK4, poly I:C, and CpG ODN were used as TLR2, TLR3, and TLR9 agonists, respectively.
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connected to TLR2 activation in cultured PBMCs. This finding 
appears to be consistent with a previous study in gout patients, 
whereby TNF-α secretion after Pam3CSK4 stimulation by PBMCs 
from gout patients was not significantly different from controls 
(38). These findings indicate that PBMCs from patients with 
AITD may be more sensitive to response induced by the agonists 
of TLRs, resulting in the secretion of pro-inflammatory cytokines.
Toll-like receptors act mainly through the adaptor molecule 
MyD88, which results in transcription of the NF-κB gene and 
activation of pro-inflammatory cytokines, such as IL-6 and 
TNF-α (39, 40). TRIF is also important to the TLR3 and TLR4 
signaling pathways. In the present study, we found increased 
expression of downstream adapter proteins MyD88 and TRIF 
in PBMCs from patients with AITD compared with controls. 
Increased mRNA expression of MyD88, TRAF6, and IRAK4 has 
been demonstrated in PBMCs from SLE patients, which corre-
lated with disease activity (41). Increased expression of MyD88 in 
B lymphocytes was also found in SLE patients but unlikely to be 
affected by disease activity (42). Increased expression of MyD88, 
TRIF, and IRAK has been found in monocytes from patients with 
T1DM (20, 43). The results of these studies are consistent with 
our results, suggesting that MyD88-dependent and -independent 
pathways are activated in the development of AITD.
Expression of endogenous ligands (HSP60 and HMGB1) for 
TLR2 and TLR4 and sRAGE was also examined in this study. We 
found HSP60 and HMGB1 levels to be significantly increased in 
the serum of AITD patients compared with controls. Moreover, 
the serum levels of sRAGE were significantly decreased in AITD 
patients. A previous study has shown that HMGB1 is overex-
pressed in the thyroid of HT patients, and HMGB1 expression 
is very low in healthy thyroids (44). Recent results also revealed 
increased numbers of HMGB1-positive monocytes in GD 
patients compared to healthy controls; with expression decreased 
by approximately 50% under antithyroid drug treatment (45). 
FigUre 8 | Dot plots showing serum levels of high mobility group box 1 (hMgB1), heat shock protein 60 (hsP60), and srage in patients with 
hashimoto’s thyroiditis, graves’s disease, and healthy controls. Serum levels of HMGB1 (a), HSP60 (B), and sRAGE (c) were measured by using 
enzyme-linked immunosorbent assay. Results are shown in the graphic. HT, Hashimoto’s thyroiditis; GD, Graves’ disease; HC, healthy controls. Level of significant is 
*P < 0.05 and **P < 0.01. Values were shown as mean ± SD. Statistical analyses were conducted using one-way ANOVA.
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FigUre 9 | correlation analysis of laboratory parameters and serum levels of high mobility group box 1 (hMgB1) and heat shock protein 60 (hsP60) 
in hT patients. Relationship between serum expression of HMGB1 with TPOAb (a) and TgAb (B), HSP60 with TPOAb (c) and TgAb (D) are presented in scatter 
plots. Pearson’s and Spearman’s correlation and P-values are given in all cases, r = Pearson correlation coefficient. HT, Hashimoto’s thyroiditis.
HSP60 is an intracellular chaperone that plays an important 
role in protein folding and stability. Kotani et  al. first demon-
strated that HSP60 is more highly expressed in HT follicular 
cells than in normal thyrocytes (46), and it has been reported 
that the serum levels of HSP60 are significantly increased in HT 
patients compared to controls (47). HSP60 is expressed in the 
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thyroid glands of HT subjects and is localized to thyrocytes. This 
previous study also reported a correlation between HSP60 and 
both TgAb and TPOAb antibodies in the serum of HT patients. 
These studies suggest that HSP60 may actively participate in the 
development of HT through antibody recognition. This is the first 
finding regarding the elevated HSP60 expression in GD patients. 
Although no studies have addressed the levels of serum HSP60 in 
GD patients, HSP70, another member of the HSP family, is highly 
expressed in the thyroid tissue of patients with GD or HT (48, 49).
The results of the current study show significantly decreased 
serum levels of sRAGE in HT and GD patients compared with 
controls. It has recently been reported that levels of sRAGE are 
significantly decreased in HT patients and that serum levels of 
AGEs are inversely correlated with those of sRAGE, a finding 
that is consistent with the results of the current study. Another 
study also showed increased expression of AGEs in HT patients, 
with positive correlations with TPOAb (50). A tendency toward 
elevated expression of AGEs in hyperthyroidism patients has 
also been reported, but this was significant only in patients with 
GD, which is consistent with our results (51). The serum levels of 
HSP60 and HMGB1 tend to correlate with TgAb and TPOAb in 
HT patients. These findings suggest that HSP60 and HMGB1 may 
play a vital role in the development of HT and are thus related to 
disease progression.
cOnclUsiOn
This is the first study reporting increased TLR expression, acti-
vation, and signaling adaptor molecules in PBMCs from AITD 
patients; a significant elevation in TLR endogenous ligands was 
also observed in the serum of AITD group. In a future study, the 
mechanism underlying the effects of viral and endogenous ligands 
on TLR activation and signaling pathways will be examined.
aUThOr cOnTriBUTiOns
Conceived and designed the experiments: WT, SP, and CL. 
Performed the experiments: SP, CL, XL, CH, TJ, SL, XZ, XH, HZ, 
XX, and CF. Analyzed the data: XW, SP, and CL. Contributed 
reagents/materials/analysis tools: WT, LS, ZS, XY, and CW. 
Contributed to the writing of the manuscript: SP and CL. All the 
authors reviewed and approved the final manuscript.
FUnDing
The study was supported by the Chinese National Natural Science 
Foundation (Grant 81400777, 81471003, 81273296, 81570708, 
and U1508219) and program for Liaoning Excellent Talents in 
University (Grant LJQ2015115).
reFerences
1. Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. 
Curr Opin Rheumatol (2007) 19(1):44–8. doi:10.1097/BOR.0b013e3280113d1a 
2. Weetman AP. Autoimmune thyroid disease: propagation and progression. 
Eur J Endocrinol (2003) 148(1):1–9. doi:10.1530/eje.0.1480001 
3. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis 
of Graves’ disease and ophthalmopathy. Endocr Rev (2003) 24(6):802–35. 
doi:10.1210/er.2002-0020 
4. Swain M, Swain T, Mohanty BK. Autoimmune thyroid disorders – an update. 
Indian J Clin Biochem (2005) 20(1):9–17. doi:10.1007/BF02893034 
5. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune 
responses. Nat Immunol (2004) 5(10):987–95. doi:10.1038/ni1112 
6. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev 
Immunol (2004) 4(7):512–20. doi:10.1038/nri1396 
7. Chuang T, Ulevitch RJ. Identification of hTLR10: a novel human toll-like 
receptor preferentially expressed in immune cells. Biochim Biophys Acta 
(2001) 1518(1–2):157–61. doi:10.1016/S0167-4781(00)00289-X 
8. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et  al. 
Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid 
dendritic cells, which activates gene transcription through MyD88. J Immunol 
(2005) 174(5):2942–50. doi:10.4049/jimmunol.174.5.2942 
9. Tsan MF, Gao B. Endogenous ligands of toll-like receptors. J Leukoc Biol 
(2004) 76(3):514–9. doi:10.1189/jlb.0304127 
10. Pace A, Barone G, Lauria A, Martorana A, Piccionello AP, Pierro P, et al. Hsp60, 
a novel target for antitumor therapy: structure-function features and pro-
spective drugs design. Curr Pharm Des (2013) 19(15):2757–64. doi:10.2174/ 
1381612811319150011 
11. Cappello F, Conway DME, Di Felice V, Zummo G, Macario AJ. Chlamydia 
trachomatis infection and anti-Hsp60 immunity: the two sides of the coin. 
PLoS Pathog (2009) 5(8):e1000552. doi:10.1371/journal.ppat.1000552 
12. Schierbeck H, Pullerits R, Pruunsild C, Fischer M, Holzinger D, Laestadius A, 
et al. HMGB1 levels are increased in patients with juvenile idiopathic arthritis, 
correlate with early onset of disease, and are independent of disease duration. 
J Rheumatol (2013) 40(9):1604–13. doi:10.3899/jrheum.120987 
13. Wirestam L, Schierbeck H, Skogh T, Gunnarsson I, Ottosson L, Erlandsson-
Harris H, et  al. Antibodies against high mobility group box protein-1 
(HMGB1) versus other anti-nuclear antibody fine-specificities and disease 
activity in systemic lupus erythematosus. Arthritis Res Ther (2015) 17:338. 
doi:10.1186/s13075-015-0856-2 
14. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin 
driving autoimmune and inflammatory disease. Nat Rev Rheumatol (2012) 
8(4):195–202. doi:10.1038/nrrheum.2011.222 
15. Beutler B. Inferences, questions and possibilities in toll-like receptor signal-
ling. Nature (2004) 430(6996):257–63. doi:10.1038/nature02761 
16. Drexler SK, Foxwell BM. The role of toll-like receptors in chronic inflamma-
tion. Int J Biochem Cell Biol (2010) 42(4):506–18. doi:10.1016/j.biocel.2009. 
10.009 
17. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNA-
associated autoantigens activate B cells by combined B cell antigen receptor/
toll-like receptor 7 engagement. J Exp Med (2005) 202(9):1171–7. doi:10.1084/
jem.20050630 
18. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong 
T, van den Hoogen FH, et  al. The expression of toll-like receptors 3 and 7 
in rheumatoid arthritis synoviun is increased and costimulation of toll-like 
receptors 3, 4 and 7/8 results in synergistic cytokine production by dendritic 
cells. Arthritis Rheum (2005) 52(8):2313–22. doi:10.1002/art.21278 
19. Devarai S, Dasu MR, Park SH, Jialal L. Increased levels of ligands of toll-
like receptors 2 and 4 in type 1 diabetes. Diabetologia (2009) 52(8):1665–8. 
doi:10.1007/s00125-009-1394-8 
20. Devarai S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal L. Increased 
toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients 
with type1 diabetes: further evidence of a proinflammatory state. J Clin 
Endocrinol Metab (2008) 93(2):578–83. doi:10.1210/jc.2007-2185 
21. Harii N, Lewis CJ, Vasko V, McCall K, Benavides-Peralta U, Sun X, et  al. 
Thyrocytes express a functional toll-like receptor 3: overexpression can 
be induced by viral infection and reversed by phenylmethimazole and is 
associated with Hashimoto’s autoimmune thyroiditis. Mol Endocrinol (2005) 
19(5):1231–50. doi:10.1210/me.2004-0100 
22. Yamazaki K, Suzuki K, Yamada E, Yamada T, Takeshita F, Matsumoto M, 
et al. Suppression of iodide uptake and thyroid hormone synthesis with stim-
ulation of the type I interferon system by double-stranded ribonucleic acid 
in cultured human thyroid follicles. Endocrinology (2007) 148(7):3226–35. 
doi:10.1210/en.2006-1638 
14
Peng et al. Toll-Like Receptors in Autoimmune Thyroid Diseases
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 578
23. Nicola JP, Velez ML, Lucero AM, Fozzatti L, Pellizas CG, Masini-Repiso AM. 
Functional toll-like receptor 4 conferring lipopolysaccharide responsiveness 
is expressed in thyroid cells. Endocrinology (2009) 150(1):500–8. doi:10.1210/
en.2008-0345 
24. Radhika A, Jacob SS, Sudhakaran PR. Influence of oxidatively modified 
LDL on monocyte-macrophage differentiation. Mol Cell Biochem (2007) 
305(1–2):133–43. doi:10.1007/s11010-007-9536-0 
25. Shi YN, Liu FH, Yu XJ, Liu ZB, Li QX, Yuan JH, et al. Polyinosine-polycytidylic 
acid promotes excessive iodine intake induced thyroiditis in non-obese dia-
betic mice via toll-like receptor 3 mediated inflammation. Chin Med J (Engl) 
(2013) 126(4):703–10. 
26. Rasooly L, Burek CL, Rose NR. Iodine-induced autoimmune thyroiditis 
in NOD-H-2h4 mice. Clin Immunol Immunopathol (1996) 81(3):287–92. 
doi:10.1006/clin.1996.0191 
27. Kawashima A, Yamazaki K, Hara T, Akama T, Yoshihara A, Sue M, et  al. 
Demonstration of innate immune responses in the thyroid gland: potential to 
sense danger and a possible trigger for autoimmune reactions. Thyroid (2013) 
23(4):477–87. doi:10.1089/thy.2011.0480 
28. Suzuki K, Mori A, Saito J, Moriyama E, Ullianich L, Kohn LD. Follicular thy-
roglobulin suppresses iodide uptake by suppressing expression of the sodium/
iodide symporter gene. Endocrinology (1999) 140(11):5422–30. doi:10.1210/
endo.140.11.7124 
29. Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and 
TLR9 in murine SLE. J Autoimmun (2009) 33(3–4):231–8. doi:10.1016/j.
jaut.2009.10.001 
30. Zhang Y, Lee AS, Shameli A, Geng X, Finegood D, Santamaria P, et  al. 
TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays 
autoimmune diabetes. J Immunol (2010) 184(10):5645–53. doi:10.4049/
jimmunol.0901814 
31. Liao WL, Chen RH, Lin HJ, Liu YH, Chen WC, Tsai Y, et  al. Toll-like 
receptor gene polymorphisms are associated with susceptibility to 
Graves’ ophthalmopathy in Taiwan males. BMC Med Genet (2010) 11:154. 
doi:10.1186/1471-2350-11-154 
32. Cho WK, Jang JP, Choi EJ, Jeon YJ, Jung IA, Kim SH, et al. Association of toll-
like receptor 10 polymorphisms with autoimmune thyroid disease in Korean 
children. Thyroid (2015) 25(2):250–5. doi:10.1089/thy.2014.0135 
33. Guan Y, Ranoa DR, Jiang S, Mutha SK, Li X, Baudry J, et al. Human TLRs 10 
and 1 share common mechanisms of innate immune sensing but not signaling. 
J Immunol (2010) 184(9):5094–103. doi:10.4049/jimmunol.0901888 
34. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 
9-dependent activation by DNA-containing immune complexes is mediated 
by HMGB1 and RAGE. Nat Immunol (2007) 8(5):487–96. doi:10.1038/ni1457 
35. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, et al. A novel 
role for HMGB1 in TLR9-mediated inflammatory response to CpG-DNA. 
Blood (2007) 110(6):1970–81. doi:10.1182/blood-2006-09-044776 
36. Ozato K, Tsujimura H, Tamura T. Toll-like receptor signaling and regulation 
of cytokine gene expression in the immune system. Biotechniques (2002) 
Suppl:66–8, 70, 72 passim. 
37. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 
21:335–76. doi:10.1146/annurev.immunol.21.120601.141126 
38. Mylona EE, Mouktaroudi M, Crisan TO, Makri S, Pistiki A, Georgitsi M, et al. 
Enhanced interleukin-1beta production of PBMCs from patients with gout 
after stimulation with toll-like receptor-2 ligands and urate crystals. Arthritis 
Res Ther (2012) 14(4):R158. doi:10.1186/ar3898 
39. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 
(2001) 1(2):135–45. doi:10.1038/35100529 
40. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive 
immunity. Adv Exp Med Biol (2005) 560:11–8. doi:10.1007/0-387-24180-9_2 
41. Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et al. Involvement 
of TLR7 MyD88-depentdent signaling pathway in the pathogenesis of 
adult-onset Still’s disease. Arthritis Res Ther (2013) 15(2):R39. doi:10.1186/
ar4193 
42. Pacheco GV, Novelo Noh IB, Velasco Cardemas RM, Amqulo Ramirez AV. 
Expression of TLR7, MyD88, NF-κB, and INF-α in B lymphocytes of Mayan 
women with systemic lupus erythematosus in Mexico. Front Immunol (2016) 
7:22. doi:10.3389/fimmu.2016.00022 
43. Dasu MR, Devaraj S, Park S, Jialal L. Increased toll-like receptor (TLR) activa-
tion and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes 
Care (2010) 33(4):861–8. doi:10.2337/dc09-1799 
44. Mardente S, Zicari A, Consorti F, Mari E, Di Vito M, Leopizzi M, et  al. 
Cross-talk between NO and HMGB1 in lymphocytic thyroiditis and papillary 
thyroid cancer. Oncol Rep (2010) 24(6):1455–61. doi:10.3892/or_00001005 
45. Mobarrez F, Abraham-Nordling M, Aguilera-Gatica K, Friberg I, Antovic A, 
Pisetsky DS, et al. The expression of microvesicles in the blood of patients with 
Graves’ disease and its relationship to treatment. Clin Endocrinol (Oxf) (2016) 
84(5):729–35. doi:10.1111/cen.12872 
46. Kotani T, Aratake Y, Hirai K, Hirai I, Ohtaki S. High expression of heat shock 
protein 60 in follicular cells of Hashimoto’s thyroiditis. Autoimmunity (1996) 
25(1):1–8. doi:10.3109/08916939608994721 
47. Marino GA, Rizzo M, Citarrella R, Rappa F, Campanella C, Bucchieri F, et al. 
Elevated blood Hsp60, its structural similarities and cross-reactivity with 
thyroid molecules, and its presence on the plasma membrane of oncocytes 
point to the chaperonin as an immunopathogenic factor in Hashimoto’s 
thyroiditis. Cell Stress Chaperones (2014) 19(3):343–53. doi:10.1007/s12192- 
013-0460-9 
48. Trieb K, Sztankay A, Hermann M, Gratzl R, Szabo J, Jindal S, et al. Do heat 
shock proteins play a role in Graves’ disease? Heat shock protein-specific 
T-cells from Graves’ disease thyroids do not recognize thyroid epithelial cells. 
J Clin Endocrinol Metab (1993) 77(2):528–35. doi:10.1210/jcem.77.2.8345059 
49. Youde SJ, Mower J, Moore DP, Parkes AB. Stress protein expression in 
primary and immortalized cultures of human thyroid cells: a model 
system for the study of stress proteins in the pathogenesis of autoimmune 
thyroid disease. Cell Stress Chaperones (1998) 3(2):89–93. doi:10.1379/1466- 
1268(1998)003<0089:SPEIPA>2.3.CO;2 
50. Ruggeri RM, Vicchio TM, Cristani M, Certo R, Caccamo D, Alibrandi A, 
et al. Oxidative stress and advanced glycation end products in Hashimoto’s 
thyroiditis. Thyroid (2016) 26(4):504–11. doi:10.1089/thy.2015.0592 
51. Caspar-Bell G, Dhar I, Prasad K. Advanced glycation end products (AGEs) 
and its receptors in the pathogenesis of hyperthyroidism. Mol Cell Biochem 
(2016) 414(1–2):171–8. doi:10.1007/s11010-016-2669-2 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Peng, Li, Wang, Liu, Han, Jin, Liu, Zhang, Zhang, He, Xie, Yu, 
Wang, Shan, Fan, Shan and Teng. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
